|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2003-3-28
|
|
pubmed:abstractText |
R115777 is a selective nonpeptidomimetic inhibitor of farnesyltransferase (FTase), one of several enzymes responsible for posttranslational modification that is required for the function of p21(ras) and other proteins. Given that RAS mutations are nearly universal in pancreatic cancer and R115777 demonstrated preclinical activity against pancreatic cell lines and xenografts, this phase II study was undertaken to determine its clinical activity and effect on target proteins in patients with measurable metastatic pancreatic adenocarcinoma.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AbbruzzeseJames LJL,
pubmed-author:AlpaughR KatherineRK,
pubmed-author:BeardMaryM,
pubmed-author:CohenSteven JSJ,
pubmed-author:HoLinusL,
pubmed-author:HudesGary RGR,
pubmed-author:LewinNancy ENE,
pubmed-author:McLaughlinSusanS,
pubmed-author:MeropolNeal JNJ,
pubmed-author:Perez-RuixoJuan JJJ,
pubmed-author:RanganathanSulabhaS,
pubmed-author:RogatkoAndréA,
pubmed-author:ThistleAmanda MAM,
pubmed-author:VerhaegheTomT,
pubmed-author:WangHaoH,
pubmed-author:WeinerLouis MLM,
pubmed-author:WrightJohn JJJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1301-6
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:12663718-Adenocarcinoma,
pubmed-meshheading:12663718-Adult,
pubmed-meshheading:12663718-Aged,
pubmed-meshheading:12663718-Alkyl and Aryl Transferases,
pubmed-meshheading:12663718-Antineoplastic Agents,
pubmed-meshheading:12663718-Carrier Proteins,
pubmed-meshheading:12663718-Disease Progression,
pubmed-meshheading:12663718-Farnesyltranstransferase,
pubmed-meshheading:12663718-Female,
pubmed-meshheading:12663718-HSP40 Heat-Shock Proteins,
pubmed-meshheading:12663718-Heat-Shock Proteins,
pubmed-meshheading:12663718-Humans,
pubmed-meshheading:12663718-Male,
pubmed-meshheading:12663718-Middle Aged,
pubmed-meshheading:12663718-Neoplasm Metastasis,
pubmed-meshheading:12663718-Pancreatic Neoplasms,
pubmed-meshheading:12663718-Quinolones,
pubmed-meshheading:12663718-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
|
|
pubmed:affiliation |
Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase II
|
